2025-08-01 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the data you provided, presented in a format suitable for a report.

## TG Therapeutics Inc. (TGTX) Stock Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** TGTX
*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**Key Performance Metrics:**

*   **TGTX Cumulative Return:** 68.37%
*   **VOO Cumulative Return:** 83.19%
*   **Absolute Divergence:** -36.3 (TGTX underperforms VOO by 36.3 percentage points)
*   **Relative Divergence:** 14.5 (The current divergence is at the 14.5th percentile of its historical range.)
    *   Range: Max = 401.1, Min = -110.5

**Analysis:** TGTX has underperformed the S&P 500 (VOO) significantly. The negative divergence suggests that TGTX's returns have lagged behind the broader market.  The relative divergence of 14.5 indicates that the current underperformance is closer to the lower end of its historical range, suggesting that while underperforming, it's not at its absolute worst relative to the S&P 500 based on the provided data.

**Alpha/Beta Analysis (Rolling 3-Year Periods):**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
| :--------- | :------ | :----- | :------ | :----- | :----- |
| 2015-2017  | -2.0%   | 2.0%   | -4.0%   | -1.4   | 1.3    |
| 2016-2018  | -54.0%  | 58.7%  | -50.0%  | -0.0   | 0.7    |
| 2017-2019  | 32.0%   | 58.7%  | 10.0%   | -0.0   | 1.8    |
| 2018-2020  | 424.0%  | 58.7%  | 397.0%  | -0.0   | 8.3    |
| 2019-2021  | 132.0%  | 63.5%  | 83.0%   | -0.0   | 3.0    |
| 2020-2022  | -84.0%  | 70.4%  | -91.0%  | 0.0    | 1.9    |
| 2021-2023  | -380.0% | 70.4%  | -400.0% | -0.7   | 2.7    |
| 2022-2024  | 72.0%   | 73.1%  | 45.0%   | -0.8   | 4.8    |
| 2023-2025  | 70.0%   | 73.1%  | 22.0%   | -0.0   | 5.6    |

**Analysis:**

*   **CAGR:** Highly variable, ranging from significant losses (-380%) to substantial gains (424%). This reflects the volatility associated with the biotechnology sector.
*   **MDD (Maximum Drawdown):**  Consistent high MDD figures indicate significant downside risk.
*   **Alpha:** Alpha is generally positive, but there are significant negative Alpha periods as well which indicates underperformance relative to the benchmark on a risk-adjusted basis during those times.
*   **Beta:** Beta values are very low or negative, suggesting TGTX's price movement is not strongly correlated with the overall market (S&P 500). This could be due to company-specific news and development.
*   **Cap(B):** Market capitalization fluctuates but generally shows growth potential.

### 2. Recent Price Action

*   **Current Price:** $35.5
*   **Previous Close:** $36.27
*   **Change:** -$2.12
*   **5-Day Moving Average:** 35.998
*   **20-Day Moving Average:** 37.2407
*   **60-Day Moving Average:** 36.3534

**Analysis:**  The current price is below all three moving averages (5, 20, and 60-day), suggesting a short-term downtrend. The change of -$2.12 (representing a noticeable drop) further confirms this downward pressure.

### 3. Market Risk Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3295 (Low Risk)
*   **RSI:** 42.66 (Neutral)
*   **PPO:** -0.76 (Bearish - below zero)
*   **Hybrid Signal:** cash_64%_Sell 9.1% of holdings (216 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** -1.5 (Short-term decrease)
*   **Expected Return:** -275.6% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates low market risk.
*   **RSI:** The RSI is below 50, suggesting bearish momentum, but is not yet oversold.
*   **PPO:** Negative PPO value indicates that the short-term moving average is below the long-term moving average, which can be interpreted as a bearish signal.
*   **Hybrid Signal:** The hybrid signal recommends a significant cash position (64%) and selling a portion of holdings, reflecting caution.
*   **Recent Relative Divergence Change:** Further confirms short-term underperformance.
*   **Expected Return:** The extremely negative expected return (-275.6%) is highly concerning, indicating a very pessimistic outlook for long-term relative performance.

### 4. Recent News & Significant Events

*   **2025-07-28:** Major business developments, regulatory changes, or market events impacting TGTX.
*   **2025-07-31:** Analyst discussions on TGTX's performance, industry trends, and global economic factors.
*   **2025-07-29:** Notable stock volatility due to recent news, earnings, or executive actions.
*   **2025-07-30:** Market experts highlight both risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The news snippets suggest a period of significant activity and scrutiny surrounding TGTX, with volatility driven by recent events. Investors should pay close attention to company announcements and analyst reports to understand the underlying drivers.

### 5. Recent Earnings Analysis:

| 날짜       | EPS   | 매출       |
| :--------- | :---- | :--------- |
| 2025-05-09 | 0.03  | 0.12 B$    |
| 2024-11-07 | 0.03  | 0.08 B$    |
| 2024-08-09 | 0.05  | 0.07 B$    |
| 2024-05-06 | -0.07 | 0.06 B$    |
| 2025-05-09 | -0.07 | 0.06 B$    |

**Analysis:**

*   The EPS has been positive in some recent quarters but also negative, indicating inconsistency in profitability.
*   Revenue has generally been increasing, although there is still a bit of fluctuation, which could reflect challenges in sales growth or market penetration.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-03-31 | \$0.12B  | 87.14%        |
| 2024-12-31 | \$0.11B  | 85.77%        |
| 2024-09-30 | \$0.08B  | 88.86%        |
| 2024-06-30 | \$0.07B  | 88.70%        |
| 2024-03-31 | \$0.06B  | 91.43%        |

**Analysis:**

*   **Revenue:** Revenue has shown a positive trend over the quarters.
*   **Profit Margin:** Profit margins are consistently high.

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-03-31 | \$0.24B  | 2.13%     |
| 2024-12-31 | \$0.22B  | 10.49%    |
| 2024-09-30 | \$0.19B  | 2.02%     |
| 2024-06-30 | \$0.18B  | 3.87%     |
| 2024-03-31 | \$0.16B  | -6.69%    |

**Analysis:**

*   **Equity:** Equity has been steadily increasing.
*   **ROE (Return on Equity):** ROE has fluctuated and was recently low, implying there could be inconsistencies in returns for shareholders.

### 7. 종합 Analysis & Conclusion

Based on the provided information, TGTX presents a mixed and concerning picture:

*   **Underperformance:** It has underperformed the S&P 500 significantly, with a negative expected return.
*   **Volatility:** The stock exhibits high volatility, as evidenced by the large swings in CAGR and MDD.
*   **Technical Indicators:** Technical indicators are bearish in the short term, with the price below key moving averages.
*   **Financials:** Revenue is generally increasing, but profit margins and ROE fluctuate.
*   **News:** Recent news suggests significant activity and scrutiny, potentially impacting the stock.
*   **Hybrid signal:** Given the MRI levels, and technicals, the system is suggesting taking a significantly defensive position with 64% cash.

**Recommendation:**  Given the underperformance, high volatility, negative expected return, and the recent bearish signals, a cautious approach is warranted. Investors should closely monitor company-specific news, analyst reports, and overall market conditions before making any investment decisions. The extremely negative expected return raises serious concerns about the long-term prospects of TGTX relative to the broader market. Waiting for more positive signals may be prudent.
